- call +1-201-465-4211
- email sales@mrinsights.biz
Inflammatory bowel disease (IBD) is a broad term used to describe disorders involving chronic inflammation of digestive tract. The disease is categorized by severe diarrhea, abdominal pain, fatigue, and weight loss.
Scope of the Report:
This report studies the Inflammatory Bowel Disease (IBD) Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Inflammatory Bowel Disease (IBD) Therapeutics market by product type and applications/end industries.
Increase in incidences of IBD and rise in adoption of anti-inflammatory drugs drive the market. In addition, strong upcoming pipeline of IBD drugs also boosts the market growth. However, side effects of these drugs over a patients body restrain the market growth. Development of biosimilars for existing drugs, and growth opportunities in the emerging economies of Asia-Pacific and LAMEA provide opportunities for the market growth.
The global Inflammatory Bowel Disease (IBD) Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Inflammatory Bowel Disease (IBD) Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Abbvie
Johnson & Johnson
GlaxoSmithKline
Merck
Novartis
Celgene
Pfizer
Salix
Roche
Teva Pharmaceutical
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Anti-inflammatory Biologics
Non-Steroidal Anti-inflammatory drugs (NSAIDs)
Corticosteroids
Market Segment by Applications, can be divided into
Hospital
Research
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Inflammatory Bowel Disease (IBD) Therapeutics Market Overview
1.1 Product Overview and Scope of Inflammatory Bowel Disease (IBD) Therapeutics
1.2 Classification of Inflammatory Bowel Disease (IBD) Therapeutics by Types
1.2.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Inflammatory Bowel Disease (IBD) Therapeutics Revenue Market Share by Types in 2017
1.2.3 Anti-inflammatory Biologics
1.2.4 Non-Steroidal Anti-inflammatory drugs (NSAIDs)
1.2.5 Corticosteroids
1.3 Global Inflammatory Bowel Disease (IBD) Therapeutics Market by Application
1.3.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital
1.3.3 Research
1.4 Global Inflammatory Bowel Disease (IBD) Therapeutics Market by Regions
1.4.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Inflammatory Bowel Disease (IBD) Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Inflammatory Bowel Disease (IBD) Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Inflammatory Bowel Disease (IBD) Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Inflammatory Bowel Disease (IBD) Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Inflammatory Bowel Disease (IBD) Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Inflammatory Bowel Disease (IBD) Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Abbvie
2.1.1 Business Overview
2.1.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Abbvie Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Johnson & Johnson
2.2.1 Business Overview
2.2.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Johnson & Johnson Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GlaxoSmithKline Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Novartis
2.5.1 Business Overview
2.5.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Novartis Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Celgene
2.6.1 Business Overview
2.6.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Celgene Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Pfizer
2.7.1 Business Overview
2.7.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Pfizer Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Salix
2.8.1 Business Overview
2.8.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Salix Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Roche
2.9.1 Business Overview
2.9.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Roche Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Teva Pharmaceutical
2.10.1 Business Overview
2.10.2 Inflammatory Bowel Disease (IBD) Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Teva Pharmaceutical Inflammatory Bowel Disease (IBD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Competition, by Players
3.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Inflammatory Bowel Disease (IBD) Therapeutics Players Market Share
3.2.2 Top 10 Inflammatory Bowel Disease (IBD) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size by Regions
4.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Market Share by Regions
4.2 North America Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries
5.1 North America Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries (2013-2018)
5.2 USA Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries
6.1 Europe Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries
7.1 Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries (2013-2018)
7.2 China Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries
8.1 South America Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Inflammatory Bowel Disease (IBD) Therapeutics by Countries
9.1 Middle East and Africa Inflammatory Bowel Disease (IBD) Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Segment by Type
10.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Forecast by Type (2018-2023)
10.3 Anti-inflammatory Biologics Revenue Growth Rate (2013-2023)
10.4 Non-Steroidal Anti-inflammatory drugs (NSAIDs) Revenue Growth Rate (2013-2023)
10.5 Corticosteroids Revenue Growth Rate (2013-2023)
11 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Segment by Application
11.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Inflammatory Bowel Disease (IBD) Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospital Revenue Growth (2013-2018)
11.4 Research Revenue Growth (2013-2018)
12 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size Forecast (2018-2023)
12.1 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Size Forecast (2018-2023)
12.2 Global Inflammatory Bowel Disease (IBD) Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Inflammatory Bowel Disease (IBD) Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Inflammatory Bowel Disease (IBD) Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Inflammatory Bowel Disease (IBD) Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Inflammatory Bowel Disease (IBD) Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Inflammatory Bowel Disease (IBD) Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Inflammatory Bowel Disease (IBD) Therapeutics Picture
Table Product Specifications of Inflammatory Bowel Disease (IBD) Therapeutics
Table Global Inflammatory Bowel D
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
